KLP Kapitalforvaltning AS Takes $634,000 Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

KLP Kapitalforvaltning AS acquired a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 16,100 shares of the company's stock, valued at approximately $634,000.

A number of other institutional investors also recently bought and sold shares of CRSP. ARK Investment Management LLC increased its position in shares of CRISPR Therapeutics by 19.7% in the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company's stock valued at $353,180,000 after acquiring an additional 1,474,439 shares during the period. State Street Corp increased its holdings in shares of CRISPR Therapeutics by 25.0% in the third quarter. State Street Corp now owns 2,992,988 shares of the company's stock valued at $140,611,000 after purchasing an additional 599,304 shares during the period. Contrarius Group Holdings Ltd purchased a new position in shares of CRISPR Therapeutics in the fourth quarter worth about $14,516,000. Raymond James Financial Inc. acquired a new stake in shares of CRISPR Therapeutics during the fourth quarter worth about $3,231,000. Finally, Van ECK Associates Corp boosted its position in CRISPR Therapeutics by 5,269.3% in the fourth quarter. Van ECK Associates Corp now owns 83,010 shares of the company's stock valued at $3,267,000 after buying an additional 81,464 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. StockNews.com raised shares of CRISPR Therapeutics to a "sell" rating in a research report on Friday, March 21st. Morgan Stanley raised their target price on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an "underweight" rating in a report on Friday, February 14th. Bank of America lowered their price target on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating on the stock in a report on Tuesday, January 7th. Stifel Nicolaus reduced their price objective on CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating for the company in a research note on Thursday, February 13th. Finally, Cantor Fitzgerald restated a "neutral" rating on shares of CRISPR Therapeutics in a research note on Wednesday, February 19th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the company's stock. Based on data from MarketBeat, CRISPR Therapeutics presently has an average rating of "Hold" and an average target price of $73.11.

Remove Ads

Insider Activity

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the transaction, the chief executive officer now directly owns 171,613 shares of the company's stock, valued at $9,473,037.60. The trade was a 9.66 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Julianne Bruno sold 1,198 shares of the firm's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $50,819.16. Following the completion of the transaction, the chief operating officer now directly owns 8,263 shares of the company's stock, valued at approximately $350,516.46. The trade was a 12.66 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 32,381 shares of company stock worth $1,608,243 over the last three months. Insiders own 4.10% of the company's stock.

CRISPR Therapeutics Stock Down 0.8 %

Shares of CRISPR Therapeutics stock traded down $0.27 during mid-day trading on Monday, reaching $32.38. 3,719,781 shares of the stock traded hands, compared to its average volume of 1,586,711. The stock has a market capitalization of $2.78 billion, a PE ratio of -7.41 and a beta of 1.85. The business has a 50-day moving average of $41.97 and a 200 day moving average of $44.52. CRISPR Therapeutics AG has a fifty-two week low of $30.11 and a fifty-two week high of $67.88.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, equities research analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.